Female hair loss treatment in New Braunfels, TX addresses one of the most emotionally difficult conditions we see in medical dermatology. Female pattern hair loss (FPHL) — also called androgenetic alopecia in women — becomes steadily more common with age. In an unselected clinic population, Birch and colleagues (Br J Dermatol, 2001) diagnosed FPHL in 6% of women under 50, rising to 38% of women aged 70 and over. A separate population survey by Gan and Sinclair (2005) found mid-frontal hair loss in 57% of women aged 80 and over. Unlike male pattern baldness, FPHL usually presents as diffuse thinning over the crown with the frontal hairline largely preserved, graded on the Ludwig scale (I–III).

Understanding Female Pattern Hair Loss
FPHL involves progressive miniaturization of scalp follicles: thick terminal hairs are gradually replaced by fine vellus hairs, and visible density falls. Messenger and Sinclair (Br J Dermatol, 2006) demonstrated this directly on scalp biopsies — across increasing severity grades, terminal follicle counts fell from 263 to 96 per cm² while vellus counts rose, and the terminal-to-vellus ratio dropped from 12.8 to 2.3. Their data also suggest miniaturization does not simply stop at a vellus hair but can progress to loss of the follicle altogether, which is the clearest argument for treating early.
FPHL is largely hereditary. According to the American Academy of Dermatology, the genes can be inherited from either parent, and because FPHL is more common after menopause, hormones appear to play a role as well. Onset can occur as early as the late teens, but most women notice it in their 40s, 50s, or 60s.
Distinguishing FPHL From Other Causes of Hair Loss
Diagnosis matters because several conditions cause diffuse thinning and each is managed differently. The differentials we work through most often include:
Telogen effluvium: diffuse shedding that follows a physiologic stressor — surgery, illness, childbirth, rapid weight loss, or significant emotional stress. Shedding typically begins two to four months after the trigger and is usually self-limited once the trigger resolves.
Thyroid dysfunction: both hypothyroidism and hyperthyroidism can cause hair loss that improves when the thyroid is treated, not with hair-specific therapy. TSH testing is a routine part of the workup.
Iron deficiency: low iron stores are associated with increased shedding in some women, so ferritin is commonly checked alongside TSH. Repleting a genuine deficiency can reduce shedding; supplementing without a deficiency does not.
Alopecia areata: an autoimmune attack on the follicle causing patchy or, less often, diffuse loss. It calls for immunologic treatment, not minoxidil alone. The same is true of other autoimmune conditions that involve the skin, including lupus and vitiligo.
Scalp inflammation: seborrheic dermatitis, scalp psoriasis, and contact dermatitis from hair products can all cause itching, scaling, and shedding that improves once the inflammation is controlled.
At Elect Dermatology, evaluation includes a clinical scalp examination, dermoscopy — which shows the variation in hair shaft caliber that characterizes FPHL — targeted laboratory testing, and a scalp biopsy when the diagnosis remains unclear. A general overview of the conditions we evaluate is on our common skin conditions page.
Minoxidil: First-Line Treatment
Topical minoxidil is the only FDA-approved treatment for female pattern hair loss and carries the strongest evidence. It prolongs the growth (anagen) phase and thickens miniaturized hairs. The Cochrane systematic review by van Zuuren and colleagues (2016), which pooled 47 randomized trials and 5,290 participants, found that significantly more women reported moderate-to-marked regrowth on minoxidil than on placebo (risk ratio 1.93), with an average increase of about 13 hairs per cm² — findings the investigators’ own assessments confirmed.
One point worth correcting, because it is widely misstated: that review found no difference in effectiveness between minoxidil 2% and 5%, and no difference in the number of adverse events between the two concentrations. Both strengths are FDA-approved for women. Choosing between them is a practical decision about formulation and tolerability, not a question of one being stronger.
What matters far more is consistency. Expect four to six months of daily use before improvement is visible, with fuller benefit around twelve months. Stopping treatment allows loss to resume over the following months. A temporary increase in shedding during the first two to eight weeks is expected and reflects follicles cycling, not treatment failure. The most common side effect is scalp irritation; some women also notice unwanted hair growth on the face, which can be limited by applying minoxidil only to the scalp and washing the face afterward.
Low-dose oral minoxidil is used off-label by dermatologists for women who cannot tolerate the topical formulation or who struggle with daily application. It is not FDA-approved for this purpose and requires discussion of blood pressure, heart rate, and fluid retention before starting, so it is a conversation to have in person rather than a product to try on your own.
Oral Medications: Spironolactone and Finasteride
Spironolactone has anti-androgenic activity and is used off-label for FPHL, particularly in women who also have hormonal acne or hirsutism. The evidence is observational rather than placebo-controlled: in Sinclair and colleagues’ study of 80 women (Br J Dermatol, 2005) treated with oral antiandrogens for at least twelve months, 44% had visible regrowth and 88% had either regrowth or no further progression. Notably, serum hormone levels did not predict who responded — which is why we do not treat FPHL as a hormone-excess problem to be corrected by lab value alone.
Finasteride deserves a frank answer. It is highly effective in male pattern baldness, but the three placebo-controlled trials of finasteride 1 mg in women pooled in the Cochrane review above showed it was no more effective than placebo. It is not FDA-approved for female hair loss and carries a risk to a developing pregnancy, requiring reliable contraception in women who could become pregnant. Some dermatologists still use it selectively at higher doses in postmenopausal women, but patients deserve to know the trial evidence in women is weak rather than being told it works as it does in men.
The Role of Nutritional Support
Iron, zinc, and vitamin D deficiencies have each been linked to increased shedding, but the evidence supports correcting a documented deficiency — not routine supplementation in women whose levels are normal. Biotin is the clearest example: it is heavily marketed for hair, has little evidence behind it in women who are not deficient, and at high doses can interfere with some laboratory immunoassays, including thyroid and troponin tests. Testing before supplementing avoids both wasted money and misleading lab results.
When to Seek Evaluation
Women who notice a widening part, more visible scalp at the crown when looking down in a mirror, or a sustained increase in daily shedding should be evaluated rather than wait. The AAD puts it plainly: treatment delivers the best results when it is started at the first sign of hair loss. That matches the biopsy findings above — once follicles are lost rather than merely miniaturized, no treatment brings them back. If you are unsure whether what you are seeing warrants a visit, our guide to how often to see a dermatologist is a reasonable starting point, and it is worth checking your scalp during a routine skin self-exam.
Noticing a widening part, a thinning crown, or more shedding than usual? Early treatment for female pattern hair loss produces meaningfully better outcomes than waiting. The board-certified dermatologists at Elect Dermatology in New Braunfels offer dermoscopy-based diagnosis and individualized medical treatment plans, including topical and low-dose oral minoxidil and spironolactone where appropriate. Call (833) 353-2875 or request an appointment to be seen at 2154 Gabriels Pl, Ste 103, New Braunfels, TX 78130. The earlier you start, the more hair there is to protect.
References
- Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144(2):297–304. PubMed
- Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184–189. PubMed
- Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol. 2006;155(5):926–930. PubMed
- van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;2016(5):CD007628. PubMed
- Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466–473. PubMed
- Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007;357(16):1620–1630. PubMed
- American Academy of Dermatology. Thinning hair and hair loss: could it be female pattern hair loss? AAD.org
Schedule Your Dermatology Appointment
Our board certified dermatologists in New Braunfels are here to help. New patients are always welcome.